Publications

European journal of cancer (Oxford, England : 1990)

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.

23-06-2026

European journal of cancer (Oxford, England : 1990)

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

18-06-2026

Cancer discovery

Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

13-05-2026

European journal of cancer (Oxford, England : 1990)

BRAF^V600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

02-05-2026

Nature

Prospective evaluation of genomics-guided off-label treatment.

01-05-2026

Nature communications

Microbiota-derived metabolites as modulators of cancer immunotherapy response.

21-04-2026

International journal of cancer

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.

15-03-2026

Nature

Regulatory grammar in human promoters uncovered by MPRA-based deep learning.

01-03-2026

Cell reports. Medicine

Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer.

17-02-2026

Molecular oncology

Strength through diversity: how cancers thrive when clones cooperate.

01-02-2026

Cell reports. Medicine

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.

20-01-2026

Cancer discovery

Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.

12-01-2026

Nature

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

01-12-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

01-12-2025

Cancer cell

Subclonal immune evasion in non-small cell lung cancer.

13-10-2025

ESMO open

Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy.

01-04-2025

ESMO open

The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

01-01-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.

02-12-2024

Nature genetics

Base editing screens define the genetic landscape of cancer drug resistance mechanisms.

01-11-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

01-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

03-09-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.

03-09-2024

Cancer discovery

Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells.

02-08-2024

The Journal of pathology

Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.

01-07-2024

Cancer treatment reviews

Agnostic drug development revisited.

01-07-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

Acta oncologica (Stockholm, Sweden)

The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).

23-05-2024

Acta oncologica (Stockholm, Sweden)

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.

23-05-2024

Scientific reports

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

16-05-2024

The oncologist

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

03-05-2024

European journal of cancer (Oxford, England : 1990)

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).

01-05-2024

Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-05-2024

Cell

A pan-cancer analysis of the microbiome in metastatic cancer.

25-04-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

01-04-2024

Cell

Generating and using real-world data: A worthwhile uphill battle.

28-03-2024

Nature protocols

Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.

01-03-2024

Genetics in medicine : official journal of the American College of Medical Genetics

Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.

01-02-2024

Nature medicine

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-02-2024

International journal of cancer

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

01-10-2023

Journal of internal medicine

Precision cancer medicine: Concepts, current practice, and future developments.

01-10-2023

Clinical advances in hematology & oncology : H&O

Repurposing drugs in oncology.

01-09-2023

The New England journal of medicine

Third-Line Therapy in Metastatic Colorectal Cancer.

13-07-2023

Cancer cell

Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

12-06-2023

Nature biotechnology

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.

01-06-2023

Cancer medicine

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

01-06-2023

Nature reviews. Clinical oncology

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.

01-05-2023

ESMO open

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.

01-04-2023

BMC cancer

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

04-03-2023

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

01-03-2023

Nature medicine

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

01-03-2023

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

Prospective evaluation of genomics-guided off-label treatment.

Microbiota-derived metabolites as modulators of cancer immunotherapy response.

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.

Regulatory grammar in human promoters uncovered by MPRA-based deep learning.

Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer.

Strength through diversity: how cancers thrive when clones cooperate.

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.

Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

Subclonal immune evasion in non-small cell lung cancer.

Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy.

The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.

Base editing screens define the genetic landscape of cancer drug resistance mechanisms.

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.

Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells.

Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.

Agnostic drug development revisited.

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

A pan-cancer analysis of the microbiome in metastatic cancer.

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

Generating and using real-world data: A worthwhile uphill battle.

Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.

Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

Precision cancer medicine: Concepts, current practice, and future developments.

Repurposing drugs in oncology.

Third-Line Therapy in Metastatic Colorectal Cancer.

Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

This site uses cookies

BRAF^V600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.